ViaCyte to Present at Cavendish Global Health Impact Forum
SAN DIEGO, May 11, 2015 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations at the upcoming healthcare event, the Cavendish Global Health Impact Forum. Dr. Paul Laikind, President and Chief Executive Officer, will give a company presentation and participate in a panel discussion hosted by CONNECT, a not-for-profit organization designed to catalyze the creation of innovative technology and life sciences companies in San Diego County. Dr. Kevin D'Amour, Vice President of Research and Chief Scientific Officer, will give a presentation and participate in a panel discussion hosted by the Sanford Consortium for Regenerative Medicine.
ViaCyte's VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.
Details of the presentations are as follows:
|
Speaker: |
Dr. Kevin D'Amour |
|
Date/Time: |
May 13, 2015, presentations start at 11:15 a.m., followed by a Q&A panel |
|
Location: |
The Scripps Research Institute, La Jolla, California |
|
Speaker: |
Dr. Paul Laikind |
|
Date/Time: |
May 14, 2015, presentations start at 4:00 p.m., followed by a Q&A panel |
|
Location: |
Robert Paine Scripps Forum for Science, Society and the Environment at Scripps Institution of Oceanography, La Jolla, California |
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte:
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte's VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information please visit www.viacyte.com. Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.
About the Cavendish Global Health Impact Forum:
The Cavendish Global Health Impact Forum is designed to showcase leading edge research and compelling new commercial technologies. The organizers hope to inspire these investors to learn more and invest in emerging technology and commercial applications of those promising therapies. Every year Cavendish Global holds three Impact Forums, one international, one on the east coast and a third event, which moves to a different global location each year. This year the third Cavendish Global Health Impact Forum will be held in La Jolla, California.
Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte
Share this article